

Enrolling Trials at Retina Research Center



Retina Research Center is currently participating in 18 Phase I-III clinical trials, 13 of which are currently enrolling.

Wet Age-Related Macular Degeneration

Genentech Archway: A Phase III study evaluating the efficacy and safety of the Port Delivery System (PDS) with ranibizumab in patients with neovascular AMD

Genentech Portal: An open-label extension study evaluating long-term safety and tolerability of the port delivery system (For patients that completed Phase II or Phase III parent study)

Novartis Merlin: A Phase III study to assess safety and efficacy of brolocizumab 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with neovascular AMD

Panoptica PAN-01-102: A Phase I/II study to evaluate safety and tolerability of PAN-90806 eye drops in treatment naïve patients with neovascular AMD

Santen 36-002 Avante: A Phase II Study assessing the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis compared to Lucentis monotherapy in subjects with neovascular AMD

Non-proliferative Diabetic Retinopathy

Boehringer-Ingelheim Protocol 1386.12 ROBIN - A Phase IIa study evaluating safety and efficacy of oral BI 1467335 in patients with moderate to severe diabetic retinopathy

Diabetic Macular Edema

Genentech Yosemite: A Phase III study to evaluate efficacy and safety of RO6867461 in patients with diabetic macular edema

Novartis Kestrel: A Phase III evaluating the efficacy of brolocizumab compared to Eylea in patients with diabetic macular edema.

Kalvista KVD001-201: A Phase 2 study to assess safety and efficacy of intravitreal plasma kallikrein inhibitor, KVD001, in patients with center-involved DME who have had prior anti-VEGF treatment

Thrombogenics THR-149-001: A Phase I, dose-escalation study to evaluate the safety of single intravitreal injection of THR-149, a kallikrein inhibitor, for treatment of DME

DRCR AC: A randomized trial comparing intravitreal Eylea versus intravitreal Avastin and deferred Eylea for treatment of center-involved DME

Macular Telangiectasia

Mactel NHOR: A natural history observation and registry study of Macular Telangiectasia Type II

Neurotech NTMT-03-B Renexus: A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2

CONTACT US

Brian B Berger, MD—bberger@e-retina.net

Saradha Chexal, MD—schexal@e-retina.net

Ivana Gunderson—igunderson@e-retina.net

Ryan Parmoon—rparmoon@e-retina.net

512-279-1251

Chirag Jhaveri, MD—cjhaveri@e-retina.net

Gowtham Jonna, MD—gjonna@e-retina.net

Daniela Wilson—dwilson@e-retina.net

Valerie Gatavaski—vgatavaski@e-retina.net

www.retinaresearchcenter.com